

GLAXOSMITHKLINE PLC
Form 6-K
March 10, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 10 March 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
- b) Position/status Chief Executive Officer
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's ShareReward Plan

- c) Price(s) and volume(s) Price(s) Volume(s)
£16.732 7 (partnership shares)
£16.732 7 (matching shares)

- d) Aggregated information

Aggregated volume Price 14 Ordinary Shares
£16.732

- e) Date of the transaction 2017-03-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
 b) Position/status CEO Designate
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares under the Company's ShareReward Plan

- c) Price(s) and volume(s) Price(s) Volume(s)
 £16.732 7 (partnership shares)
 £16.732 7 (matching shares)

- d) Aggregated information 14 Ordinary Shares
 Aggregated volume Price £16.732

- e) Date of the transaction 2017-03-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
 b) Position/status President, Global Manufacturing & Supply

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's ShareReward Plan
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.732 | 7 (partnership shares) |
| £16.732 | 7 (matching shares) |
- d) Aggregated information
- | Aggregated volume | Price |
|--------------------|---------|
| 14 Ordinary Shares | £16.732 |
- e) Date of the transaction 2017-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882

	Acquisition of Ordinary Shares under the Company's ShareReward Plan
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£16.732 7 (partnership shares) £16.732 7 (matching shares)
	Aggregated information
d) Aggregated volume Price	14 Ordinary Shares £16.732
e) Date of the transaction	2017-03-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan
	Price(s) Volume(s)
c) Price(s) and volume(s)	£16.732 7 (partnership shares) £16.732 7 (matching shares)
d) Aggregated information	
Aggregated volume Price	14 Ordinary Shares £16.732

e) Date of the transaction 2017-03-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain
 b) Position/status President, Global
 Pharmaceuticals

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's
 ShareReward Plan

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.732 7 (partnership shares)
 £16.732 7 (matching shares)

d) Aggregated information 14 Ordinary Shares
 Aggregated volume Price £16.732

e) Date of the transaction 2017-03-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Acquisition of Ordinary Shares under the Company's ShareReward Plan
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.732 | 7 (partnership shares) |
| £16.732 | 7 (matching shares) |
- d) Aggregated information
- | Aggregated volume | Price |
|--------------------|---------|
| 14 Ordinary Shares | £16.732 |
- e) Date of the transaction 2017-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.732 7 (partnership shares) £16.732 7 (matching shares)
d) Aggregated information	14 Ordinary Shares
Aggregated volume Price	£16.732
e) Date of the transaction	2017-03-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr P C Thomson
b) Position/status	SVP, Communications & Government Affairs
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.732 7 (partnership shares) £16.732 7 (matching shares)
d) Aggregated information	14 Ordinary Shares
Aggregated volume Price	£16.732

- e) Date of the transaction 2017-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's ShareReward Plan

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.732	7 (partnership shares)
£16.732	7 (matching shares)

- d) Aggregated information

Aggregated volume	14 Ordinary Shares
Price	£16.732

- e) Date of the transaction 2017-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- | | |
|---|---|
| b) Position/status | Company Secretary |
| c) Initial notification/
amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| | ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan |
| c) Price(s) and volume(s) | Price(s) Volume(s)
£16.732 7 (partnership shares)
£16.732 7 (matching shares) |
| d) Aggregated information | 14 Ordinary Shares |
| Aggregated volume Price | £16.732 |
| e) Date of the transaction | 2017-03-09 |
| f) Place of the transaction | London Stock Exchange (XLON) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 10, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc